A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who have failed previous tumor necrosis factor-alpha (TNF-a) antagonists. - Effect of SAR153191with Methotrexate in patients with active rheumatoid arthritis who failed TNF-a

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2011
This article has no abstract
Epistemonikos ID: f54845557fb1a581f723c87eb0bdbfa763f92ab4
First added on: Apr 16, 2025